The global Blood Gas Analyzer Market, valued at US$2.61 billion in 2024, stood at US$2.70 billion in 2025 and is projected to advance at a resilient CAGR of 4.6% from 2025 to 2030, culminating in a forecasted valuation of US$3.38 billion by the end of the period. Growth is being driven by the rising prevalence of chronic and acute diseases, increasing demand for rapid and accurate diagnostics, and continuous advancements in blood gas analyzer technology. The adoption of point-of-care testing in critical care, emergency, and respiratory management settings further supports market expansion. The growing focus on improving patient outcomes and optimizing clinical workflows encourages healthcare providers to invest in modern analyzers. Additionally, expanding healthcare infrastructure in developing regions presents new opportunities for market players to capture untapped demand.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242278963

By sample type, the blood gas analyzer market is segmented based on sample type into arterial, venous, and capillary blood. In 2024, the arterial blood segment held the largest share of the market, as it provides the most accurate and reliable measurement of oxygen, carbon dioxide, and pH levels, which are critical for patient assessment. Arterial sampling is widely preferred in hospitals and critical care settings for routine monitoring and clinical decision-making, driving higher demand.

By application, the blood gas analyzer market is segmented by application into critical care management, respiratory care, emergency care management, and other applications. In 2024, critical care management held the largest share, as patients in intensive care units require frequent monitoring of blood gas levels to manage critical and unstable health conditions. The high frequency of testing in ICUs, where multiple measurements may be performed per patient daily, drives substantial demand for blood gas analyzers in this application area.

By geography, the blood gas analyzer market is divided into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held the largest share, primarily driven by its well-established diagnostics ecosystem, with the US as the primary contributor. This regional dominance is supported by strong healthcare infrastructure, a high prevalence of chronic and acute diseases, and significant investments in advanced diagnostic technologies and innovations.

The major players operating in this market are Danaher Corporation (US), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Nova Biomedical (US), Medica Corporation (US), Techno Medica Co., Ltd. (Japan), IDEXX Laboratories, Inc. (US), EDAN Instruments, Inc. (China), and Guangzhou Wondfo Biotech Co., Ltd. (China).

RECENT DEVELOPMENTS

• April 2025 : F. Hoffmann-La Roche Ltd. (Switzerland) announced plans to invest USD 50 billion in the US over five years, further enhancing its strong presence in the country.
• July 2024 : Werfen S.A. (Spain) launched the GEM Premier 7000 with Intelligent Quality Management 3 (iQM3) after receiving 510(k) clearance from the US Food and Drug Administration. The GEM Premier 7000 with iQM3 is the first point-of-care (POC) system to offer hemolysis detection, enhancing the reliability of blood gas testing.
• May 2024 : Danaher Corporation (US) partnered with Etiometry (US), a clinical decision-support software provider, to improve decision-making and workflows in critical care. By integrating the Etiometry platform with Radiometer’s acute care diagnostics, clinicians can view blood gas results together with physiological parameters and other essential clinical data on a unified interface.
• October 2023 : Nova Biomedical (US) received 510(k) clearance from the US Food and Drug Administration (FDA) for the micro capillary sample mode on the Stat Profile Prime Plus Critical Care Analyzer.
• February 2023 : Siemens Healthineers AG (Germany) and Unilabs (Switzerland), a leading diagnostic services provider, have announced a multi-year agreement. As part of this agreement, Unilabs will enhance its laboratory infrastructure by investing in Siemens Healthineers’ advanced technology and acquiring over 400 laboratory analyzers.

For more information, Inquire Now!